Priligy

Priligy Contraindications

dapoxetine

Manufacturer:

A. Menarini

Distributor:

Zuellig
Full Prescribing Info
Contraindications
Hypersensitivity to the active substance or to any of the excipients (see Description).
Significant pathological cardiac conditions such as: Heart failure (NYHA class II-IV); conduction abnormalities such as AV block or sick sinus syndrome; significant ischemic heart disease; significant valvular disease; a history of syncope; a history of mania or severe depression. Concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing treatment with a MAOI. Similarly, a MAOI should not be administered within 7 days after Priligy has been discontinued (see Interactions).
Concomitant treatment with thioridazine, or within 14 days of discontinuing treatment with thioridazine. Similarly, thioridazine should not be administered within 7 days after Priligy has been discontinued (see Interactions).
Concomitant treatment with serotonin reuptake inhibitors [selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs)] or other medicinal/herbal products with serotonergic effects [e.g., L-tryptophan, triptans, tramadol, linezolid, lithium, St. John's Wort (Hypericum perforatum)] or within 14 days of discontinuing treatment with these medicinal/herbal products. Similarly, these medicinal/herbal products should not be administered within 7 days after Priligy has been discontinued (see Interactions).
Concomitant treatment of potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazadone, nelfinavir, atazanavir, etc. (see Interactions).
Moderate and severe hepatic impairment.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in